In a recent press release, Fresenius Kabi has announced the release of the first and only FDA-approved lipid emultion to address nutritional needs of pediatric patients suffering from life-threatening conditions.
Editor's Note: This article originally appeared on Fresenius Kabi's website.
Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today that Omegaven® (fish oil triglycerides) injectable emulsion is now commercially available in the United States. This novel lipid had previously been available only for compassionate use in the U.S.
Omegaven is an intravenous lipid emulsion that provides calories and fatty acids for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. Omegaven is the first and only FDA-approved fish oil lipid emulsion for this condition. Click here to continue>>
News from our partners.